HRP20240346T1 - Esterski i karbonatni spojevi pirimidina kao inhibitori jak-kinaze - Google Patents
Esterski i karbonatni spojevi pirimidina kao inhibitori jak-kinaze Download PDFInfo
- Publication number
- HRP20240346T1 HRP20240346T1 HRP20240346TT HRP20240346T HRP20240346T1 HR P20240346 T1 HRP20240346 T1 HR P20240346T1 HR P20240346T T HRP20240346T T HR P20240346TT HR P20240346 T HRP20240346 T HR P20240346T HR P20240346 T1 HRP20240346 T1 HR P20240346T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound
- alkyl
- image
- Prior art date
Links
- FNKLZPHAAKLNBX-UHFFFAOYSA-N carbonic acid;pyrimidine Chemical class OC(O)=O.C1=CN=CN=C1 FNKLZPHAAKLNBX-UHFFFAOYSA-N 0.000 title 1
- 150000002148 esters Chemical class 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 21
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 206010012438 Dermatitis atopic Diseases 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 4
- 201000008937 atopic dermatitis Diseases 0.000 claims 4
- 208000037896 autoimmune cutaneous disease Diseases 0.000 claims 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 3
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 3
- 201000004624 Dermatitis Diseases 0.000 claims 3
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 201000011486 lichen planus Diseases 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 1
- 206010001764 Alopecia scarring Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 208000011738 Lichen planopilaris Diseases 0.000 claims 1
- 206010024434 Lichen sclerosus Diseases 0.000 claims 1
- 201000009053 Neurodermatitis Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000031709 Skin Manifestations Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 208000017940 prurigo nodularis Diseases 0.000 claims 1
- 208000037851 severe atopic dermatitis Diseases 0.000 claims 1
- 150000003527 tetrahydropyrans Chemical class 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962837829P | 2019-04-24 | 2019-04-24 | |
| PCT/US2020/029465 WO2020219639A1 (en) | 2019-04-24 | 2020-04-23 | Ester and carbonate pyrimidine compounds as jak kinase inhibitors |
| EP20726591.9A EP3958969B1 (en) | 2019-04-24 | 2020-04-23 | Ester and carbonate pyrimidine compounds as jak kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240346T1 true HRP20240346T1 (hr) | 2024-05-24 |
Family
ID=70740750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240346TT HRP20240346T1 (hr) | 2019-04-24 | 2020-04-23 | Esterski i karbonatni spojevi pirimidina kao inhibitori jak-kinaze |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11155549B2 (enExample) |
| EP (1) | EP3958969B1 (enExample) |
| JP (1) | JP7470713B2 (enExample) |
| AR (1) | AR118768A1 (enExample) |
| CA (1) | CA3135383A1 (enExample) |
| ES (1) | ES2974577T3 (enExample) |
| HR (1) | HRP20240346T1 (enExample) |
| HU (1) | HUE066802T2 (enExample) |
| PL (1) | PL3958969T3 (enExample) |
| TW (1) | TW202106682A (enExample) |
| WO (1) | WO2020219639A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA49956B1 (fr) | 2017-10-27 | 2022-11-30 | Theravance Biopharma R&D Ip Llc | Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak |
| JP7470713B2 (ja) * | 2019-04-24 | 2024-04-18 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Ｊａｋキナーゼ阻害剤としてのエステルおよびカルボナートピリミジン化合物 |
| JP7482152B2 (ja) * | 2019-04-24 | 2024-05-13 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | 皮膚疾患の処置のためのピリミジンｊａｋ阻害剤 発明の背景 |
| US20210212962A1 (en) * | 2020-01-13 | 2021-07-15 | Sol-Gel Technologies Ltd. | Methods and compositions for the treatment of granuloma annulare or subcutaneous inflammation and non-infection granulomatous diseases |
| AU2022263067A1 (en) * | 2021-04-22 | 2023-11-02 | Shenzhen Chipscreen Biosciences Co., Ltd. | Pharmaceutical composition containing jak3/jak1/tbk1 selective inhibitor and medical use thereof |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4919934A (en) | 1989-03-02 | 1990-04-24 | Richardson-Vicks Inc. | Cosmetic sticks |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| AU2001290912A1 (en) | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| BR0116493A (pt) | 2000-12-21 | 2003-09-30 | Vertex Pharma | Compostos de pirazol úteis como inibidores de proteìna cinase |
| ATE508126T1 (de) | 2005-11-16 | 2011-05-15 | Vertex Pharma | Als kinaseinhibitoren geeignete aminopyrimidine |
| TW200817391A (en) | 2006-06-30 | 2008-04-16 | Astrazeneca Ab | Novel compounds |
| AU2007269540B2 (en) | 2006-07-05 | 2013-06-27 | Exelixis, Inc. | Methods of using IGF1R and Abl kinase modulators |
| RU2014129740A (ru) | 2011-12-22 | 2016-02-10 | Ф.Хоффманн-Ля Рош Аг | Производные 2,4-диаминопиримидина в качестве ингибиторов серин/треонин киназы |
| WO2015094803A1 (en) | 2013-12-16 | 2015-06-25 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| NO2721710T3 (enExample) * | 2014-08-21 | 2018-03-31 | ||
| ES2924698T3 (es) | 2015-05-28 | 2022-10-10 | Theravance Biopharma R&D Ip Llc | Proceso e intermedios para la preparación de compuestos de naftiridina como inhibidores de quinasa JAK |
| WO2017189822A1 (en) | 2016-04-28 | 2017-11-02 | Theravance Biopharma R&D Ip, Llc | Pyrimidine compounds as jak kinase inhibitors |
| MA49956B1 (fr) | 2017-10-27 | 2022-11-30 | Theravance Biopharma R&D Ip Llc | Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak |
| TWI740288B (zh) | 2018-11-27 | 2021-09-21 | 大陸商江蘇豪森藥業集團有限公司 | 含氮雜芳類衍生物調節劑、其製備方法和應用 |
| CN115925705B (zh) | 2018-11-30 | 2024-12-31 | 江苏豪森药业集团有限公司 | 杂芳类衍生物调节剂、其制备方法和应用 |
| JP7482152B2 (ja) | 2019-04-24 | 2024-05-13 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | 皮膚疾患の処置のためのピリミジンｊａｋ阻害剤 発明の背景 |
| JP7470713B2 (ja) | 2019-04-24 | 2024-04-18 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Ｊａｋキナーゼ阻害剤としてのエステルおよびカルボナートピリミジン化合物 |
| CN113372364B (zh) | 2020-03-10 | 2024-05-31 | 明慧医药（上海）有限公司 | 一类jak激酶抑制剂及其制备和应用 |
| CN113372351A (zh) | 2020-03-10 | 2021-09-10 | 明慧医药（杭州）有限公司 | 一类jak激酶抑制剂及其制备和应用 |
-
2020
- 2020-04-23 JP JP2021562810A patent/JP7470713B2/ja active Active
- 2020-04-23 PL PL20726591.9T patent/PL3958969T3/pl unknown
- 2020-04-23 TW TW109113575A patent/TW202106682A/zh unknown
- 2020-04-23 ES ES20726591T patent/ES2974577T3/es active Active
- 2020-04-23 AR ARP200101152A patent/AR118768A1/es unknown
- 2020-04-23 HR HRP20240346TT patent/HRP20240346T1/hr unknown
- 2020-04-23 EP EP20726591.9A patent/EP3958969B1/en active Active
- 2020-04-23 CA CA3135383A patent/CA3135383A1/en active Pending
- 2020-04-23 WO PCT/US2020/029465 patent/WO2020219639A1/en not_active Ceased
- 2020-04-23 HU HUE20726591A patent/HUE066802T2/hu unknown
- 2020-04-23 US US16/856,280 patent/US11155549B2/en active Active
-
2021
- 2021-09-27 US US17/448,922 patent/US11845747B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2974577T3 (es) | 2024-06-27 |
| US11155549B2 (en) | 2021-10-26 |
| EP3958969B1 (en) | 2024-01-10 |
| TW202106682A (zh) | 2021-02-16 |
| PL3958969T3 (pl) | 2024-05-20 |
| JP7470713B2 (ja) | 2024-04-18 |
| CA3135383A1 (en) | 2020-10-29 |
| US20220009926A1 (en) | 2022-01-13 |
| EP3958969C0 (en) | 2024-01-10 |
| WO2020219639A1 (en) | 2020-10-29 |
| AR118768A1 (es) | 2021-10-27 |
| JP2022529370A (ja) | 2022-06-21 |
| US20200339580A1 (en) | 2020-10-29 |
| HUE066802T2 (hu) | 2024-09-28 |
| EP3958969A1 (en) | 2022-03-02 |
| US11845747B2 (en) | 2023-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20241053T1 (hr) | Pirimidinski inhibitori jak, namijenjeni liječenju kožnih bolesti | |
| JP2022529370A5 (enExample) | ||
| KR102518945B1 (ko) | 단백질 키나제 c 억제제 및 그의 사용 방법 | |
| KR102711990B1 (ko) | 골관절염의 치료를 위한 에이디에이엠티에스 억제제로서 5-[(피페라진-1-일)-3-옥소-프로필]-이미다졸리딘-2,4-디온 유도체 | |
| JP2020040960A (ja) | オートタキシンの置換スピロ環式阻害剤 | |
| AR118768A1 (es) | Derivados de pirimidina como inhibidores de las cinasas jak | |
| HRP20100180T1 (hr) | Novi spoj piridazina i njegova primjena | |
| HRP20110289T1 (hr) | Makrociklički inhibitori virusa hepatitisa c | |
| SK17342002A3 (sk) | Derivát pyrolo[2,3-d]pyrimidínu ako činidlo potlačujúce imunitu | |
| UA110347C2 (uk) | ПОХІДНІ 6-ЦИКЛОАЛКІЛ-1,5-ДИГІДРОПІРАЗОЛО[3,4-d]ПІРИМІДИН-4-ОНУ І ЇХ ЗАСТОСУВАННЯ ЯК ІНГІБІТОРІВ PDE9A | |
| JP2003527328A (ja) | チロシンキナーゼのインヒビターとして有益な複素環化合物 | |
| HRP20221018T1 (hr) | Liječenje katapleksije | |
| AR071283A1 (es) | Compuestos heterociclicos y usos de los mismos | |
| HRP20141108T1 (hr) | Antagonisti piperidinon karboksamid azaindan cgrp receptora | |
| AR057109A1 (es) | Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis | |
| NZ592238A (en) | Pharmaceutical compositions comprising 4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine derivatives | |
| AR044940A1 (es) | Compuestos heterociclicos y su uso como moduladores de gamma opioides | |
| HRP20171425T1 (hr) | Derivati oksazolidin-2-on-pirimidina | |
| HRP20211801T1 (hr) | Derivati kinolin-2-ona | |
| WO2024112621A1 (en) | 2-amino-n-(4-amino-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)butan-2-yl)benzamide derivatives as protease inhibitors for treating or preventing coronavirus infection | |
| FI81574B (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 2,4-diamino-5,8-dihydro-pyrido/2,3-d/ pyrimidin-6-karboxylsyraesterderivat. | |
| WO2024246837A1 (en) | Inhibitors of canine janus kinase and uses thereof | |
| GB1435916A (en) | Pharmaceutical weight-reducing compositions | |
| SE8305917D0 (sv) | Mellanprodukter for anvendning vid framstellning av hexahydro-gamma-karbolinforeningar | |
| ES8307788A1 (es) | Procedimiento perfeccionado para la fabricacion de derivadosde la quinolina |